Author:
Hofmann M,Große-Hovest L,Nübling T,Pyż E,Bamberg M L,Aulwurm S,Bühring H-J,Schwartz K,Haen S P,Schilbach K,Rammensee H-G,Salih H R,Jung G
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference35 articles.
1. Oflazoglu E, Audoly LP . Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2: 14–19.
2. Beck A, Wurch T, Bailly C, Corvaia N . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345–352.
3. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466–3473.
4. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103: 4005–4010.
5. Robak T . GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009; 10: 588–596.
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献